Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 12/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15635838 | 1.00 | CTSA (0.55) | CTSAALDH1A1THRBHPGDNPSR1 | |
| SCHEMBL15635973 | 0.92 | CTSA (0.54) | CTSAALDH1A1THRBHPGDNPSR1 | |
| SCHEMBL15635964 | 0.92 | CTSA (0.54) | CTSADHODHMMECYP3A4 | |
| SCHEMBL15636099 | 0.91 | CTSA (0.55) | CTSAALDH1A1THRBHPGDNPSR1 | |
| SCHEMBL15636824 | 0.91 | CYP26A1 (0.53) | CTSAALDH1A1DHODHCYP26A1MME | |
| SCHEMBL15636978 | 0.91 | CYP26A1 (0.53) | CTSAALDH1A1DHODHCYP26A1MME | |
| SCHEMBL15636741 | 0.91 | CTSA (0.59) | CTSACYP26A1MMECYP3A4 | |
| SCHEMBL15636682 | 0.90 | CTSA (0.54) | CTSAALDH1A1THRBHPGDNPSR1 | |
| SCHEMBL15636490 | 0.89 | CYP26A1 (0.50) | CTSACYP26A1MMECYP3A4 | |
| SCHEMBL15637590 | 0.88 | CTSA (0.59) | CTSAALDH1A1THRBHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664257-B2 | Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-03-04 | — | — | US | claimed |
| US-20130046004-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-02-21 | — | — | US | claimed |
| EP-2528902-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-12-05 | — | — | EP | claimed |
| WO-2011092187-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2011-08-04 | — | — | WO | claimed |
| US-20140128616-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-05-08 | — | — | US | disclosed |
| WO-2014053533-A1 | USE OF SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AS PHARMACEUTICALS FOR PREVENTION/TREATMENT OF ATRIAL FIBRILLATION | SANOFI (FR) | 2014-04-10 | — | — | WO | disclosed |
| US-8664257-B2 | Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2014-03-04 | — | — | US | disclosed |
| US-20130046004-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-02-21 | — | — | US | disclosed |
| EP-2528902-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092187-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046004-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CTSF, CTSS, CTSE | CTSA 10/4885ALDH1A1 581/4885THRB 2602/4885 |
| US-20140128616-A1 | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | CTSF, CTSS, CTSE | CTSA 10/4885ALDH1A1 581/4885THRB 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.